Signatera and IBC: Understanding the Promise—and the Limitations
Editor’s Note: This article was developed from a podcast conversation and has been edited for clarity, readability, and length while preserving the original insights and intent of the discussion. In recent months, many inflammatory breast cancer (IBC) patients...
Recap: Dana Farber Inflammatory Breast Cancer Program 8th Annual Patient Forum
Blog by Trish Vickery On April 11, the Dana Farber IBC team held their annual patient forum; the virtual format allowed patients near and far to join. The day included informative medical presentations, followed by an expert roundtable, with a new feature –...
FDA Approves Vepdegestrant for ER+/HER2– Advanced Breast Cancer With an ESR1 Mutation
The FDA has approved vepdegestrant (Veppanu) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer who have progressed after at least one line of endocrine therapy. Angela Alexander, PhD, Sr Clinical Studies Coordinator –...
When Someone Says “It’s All the Same at Stage IV”… It’s Time to Ask Better Questions
by Terry Lynn Arnold Too many women newly diagnosed with stage IV inflammatory breast cancer (IBC) are being told that the type of cancer no longer matters. That statement should raise serious questions. Because it’s not true. IBC Is Different—From the Very Beginning...